Blank Rome Represents Cancer Prevention Pharmaceuticals in Definitive Agreement and Planned Merger with Panbela Therapeutics
A Blank Rome deal team represented Cancer Prevention Pharmaceuticals, Inc. (“CPP”), in connection with its entry into a definitive agreement and plan of merger with Panbela Therapeutics Inc. (Nasdaq: PBLA) for a combination of Panbela Therapeutics stock and up to $60 million of future milestone and royalty payments. The transaction is expected to close by the second quarter of 2022.
CPP is a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases. The combined entity will have an expanded pipeline addressing an estimated aggregate five-billion-dollar market opportunity for the research/program areas of initial focus.
For more information, please read Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc. (press release, February 22, 2022).
The Blank Rome deal team is led by Leslie Marlow and Hank Gracin.